Clariane Toekomstige groei

Future criteriumcontroles 3/6

Clariane zal naar verwachting groeien in winst en omzet met respectievelijk 112% en 4.9% per jaar. De winst per aandeel zal naar verwachting groeien met 132.8% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 3% zijn.

Belangrijke informatie

112.0%

Groei van de winst

132.8%

Groei van de winst per aandeel

Healthcare winstgroei	21.5%
Inkomstengroei	4.9%
Toekomstig rendement op eigen vermogen	3.0%
Dekking van analisten	Low
Laatst bijgewerkt	29 Oct 2024

Recente toekomstige groei-updates

Recent updates

Here's Why Clariane (EPA:CLARI) Has A Meaningful Debt Burden

Sep 13

Clariane SE's (EPA:CLARI) 26% Cheaper Price Remains In Tune With Revenues

Aug 06

Here's Why It's Unlikely That Clariane SE's (EPA:CLARI) CEO Will See A Pay Rise This Year

Jun 04

Clariane SE (EPA:CLARI) Shares Could Be 33% Below Their Intrinsic Value Estimate

May 22

Market Participants Recognise Clariane SE's (EPA:CLARI) Revenues Pushing Shares 187% Higher

May 22

Winst- en omzetgroeiprognoses

ENXTPA:CLARI - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	5,832	161	627	915	4
12/31/2025	5,531	94	543	832	4
12/31/2024	5,254	-46	495	754	3
6/30/2024	5,170	-129	570	934	N/A
3/31/2024	5,083	-111	445	869	N/A
12/31/2023	4,996	-92	320	804	N/A
9/30/2023	4,865	-32	244	799	N/A
6/30/2023	4,735	28	168	794	N/A
3/31/2023	4,587	32	204	828	N/A
12/31/2022	4,438	36	239	862	N/A
6/30/2022	4,288	85	348	900	N/A
3/31/2022	4,212	92	330	870	N/A
12/31/2021	4,137	100	311	840	N/A
9/30/2021	4,047	76	279	818	N/A
6/30/2021	3,941	60	243	785	N/A
3/31/2021	3,857	50	259	790	N/A
12/31/2020	3,773	39	275	795	N/A
9/30/2020	3,728	57	310	765	N/A
6/30/2020	3,683	74	346	734	N/A
3/31/2020	3,648	94	393	750	N/A
12/31/2019	3,613	115	439	766	N/A
9/30/2019	3,542	117	352	687	N/A
6/30/2019	3,471	119	264	607	N/A
3/31/2019	3,404	121	188	492	N/A
12/31/2018	3,336	123	113	377	N/A
9/30/2018	3,280	152	139	371	N/A
6/30/2018	3,224	180	165	364	N/A
3/31/2018	3,177	172	N/A	375	N/A
12/31/2017	3,131	163	N/A	385	N/A
9/30/2017	3,091	150	N/A	353	N/A
6/30/2017	3,052	137	N/A	320	N/A
3/31/2017	3,017	134	N/A	314	N/A
12/31/2016	2,981	131	N/A	307	N/A
9/30/2016	2,880	87	N/A	296	N/A
6/30/2016	2,779	42	N/A	284	N/A
3/31/2016	2,676	50	N/A	264	N/A
12/31/2015	2,573	59	N/A	245	N/A
9/30/2015	2,553	77	N/A	271	N/A
6/30/2015	2,533	95	N/A	297	N/A
3/31/2015	2,378	78	N/A	272	N/A
12/31/2014	2,222	61	N/A	247	N/A
9/30/2014	1,938	44	N/A	186	N/A
6/30/2014	1,654	27	N/A	126	N/A
3/31/2014	1,505	28	N/A	122	N/A
12/31/2013	1,356	29	N/A	119	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat CLARI de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 1.2% ).

Winst versus markt: Er wordt verwacht dat CLARI de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat CLARI binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van CLARI ( 4.9% per jaar) zal naar verwachting langzamer groeien dan de markt French ( 5.6% per jaar).

Hoge groei-inkomsten: De omzet van CLARI ( 4.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen CLARI zal naar verwachting over 3 jaar laag zijn ( 3 %).

Clariane Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Clariane Se Provides Earnings Guidance for the Full Year 2024; Reiterates Earnings Guidance for the Full Year from 2023 to 2026

Price target increased by 82% to €7.90

Price target decreased by 12% to €3.83

Price target decreased by 11% to €4.01

Price target decreased by 22% to €6.73

Price target decreased by 11% to €10.44

Recent updates

Clariane SE, Annual General Meeting, May 14, 2025

Clariane SE to Report Fiscal Year 2024 Results on Feb 24, 2025

Clariane Group Announces Management Changes

Here's Why Clariane (EPA:CLARI) Has A Meaningful Debt Burden

Clariane Se Provides Earnings Guidance for the Full Year 2024; Reiterates Earnings Guidance for the Full Year from 2023 to 2026

Clariane SE's (EPA:CLARI) 26% Cheaper Price Remains In Tune With Revenues

New major risk - Shareholder dilution

Now 20% undervalued

Odalys SA acquired Les Essentielles - SARL from Clariane SE (ENXTPA:CLARI).

Price target increased by 82% to €7.90

New minor risk - Shareholder dilution

Clariane SE has filed a Follow-on Equity Offering in the amount of €237.083186 million.

Clariane SE Appoints Sylvia Metayer as Non-Executive Director

Here's Why It's Unlikely That Clariane SE's (EPA:CLARI) CEO Will See A Pay Rise This Year

Clariane SE (EPA:CLARI) Shares Could Be 33% Below Their Intrinsic Value Estimate

Market Participants Recognise Clariane SE's (EPA:CLARI) Revenues Pushing Shares 187% Higher

Clariane (EPA:CLARI) Takes On Some Risk With Its Use Of Debt

Price target decreased by 12% to €3.83

Clariane Confirms Rumor of Disposal of HAD/SSIAD Business in France

Price target decreased by 11% to €4.01

Full year 2023 earnings released

Elevation Healthcare Properties managed by Elevation Advisors signed an agreement to acquire Berkley Care Group Ltd from Clariane SE (ENXTPA:CLARI) for £207 million.

Investor sentiment deteriorates as stock falls 22%

Investor sentiment deteriorates as stock falls 18%

Clariane SE to Report First Half, 2024 Results on Jul 30, 2024

Is It Too Late To Consider Buying Clariane SE (EPA:CLARI)?

Price target decreased by 22% to €6.73

Investor sentiment deteriorates as stock falls 17%

These 4 Measures Indicate That Clariane (EPA:CLARI) Is Using Debt Extensively

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 31%

Clariane SE to Report Fiscal Year 2023 Results on Feb 28, 2024

Now 20% undervalued after recent price drop

Calculating The Fair Value Of Clariane SE (EPA:CLARI)

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 11% to €10.44

Consensus EPS estimates fall by 82%

What Is Clariane SE's (EPA:CLARI) Share Price Doing?

First half 2023 earnings released

Clariane Announces Dividend for the Financial Year 2022, Payable on July 13, 2023

Clariane Announces Dividend for the Financial Year 2022, Payable on July 13, 2023

Upcoming dividend of €0.25 per share at 3.3% yield

Consensus EPS estimates increase by 18%

Now 21% undervalued after recent price drop

At €6.98, Is It Time To Put Korian (EPA:KORI) On Your Watch List?

These 4 Measures Indicate That Korian (EPA:KORI) Is Using Debt Extensively

Consensus EPS estimates increase by 20%

Price target decreased by 11% to €20.50

Investor sentiment deteriorates as stock falls 19%

Consensus EPS estimates fall by 50%, revenue upgraded

Price target decreased by 8.2% to €21.63

Full year 2022 earnings released

Price target decreased by 7.4% to €21.94

A Look At The Fair Value Of Korian (EPA:KORI)

Korian (ENXTPA:KORI) acquired Grupo 5 Acción y Gestión Social, S.A. from Corpfin Capital Asesores, S.A., SGEIC and others.

Should You Think About Buying Korian (EPA:KORI) Now?

Korian to Report First Half, 2023 Results on Jul 27, 2023

Does Korian (EPA:KORI) Have A Healthy Balance Sheet?

Consensus forecasts updated

Price target decreased to €24.69

Investor sentiment deteriorated over the past week

Is There Now An Opportunity In Korian (EPA:KORI)?

Is Korian (EPA:KORI) A Risky Investment?

First half 2022 earnings released

Korian Appoints Philippe Lévêque as Director and Chairman of the Ethics, Quality and CSR Committee

Upcoming dividend of €0.35 per share

Why Korian (EPA:KORI) Could Be Worth Watching

Investor sentiment deteriorated over the past week